Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Stroke, Problem of Aging
Interventions: desferrioxamine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Placebos, Ketamine, Nitroprusside; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Premenstrual Syndrome, Menstrual Pain
Interventions: DITTO Cycle Supplement; Dietary Supplement
Lead sponsor: Muse Nutrition Ltd; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Anemia, Iron Deficiency
Interventions: Ferric maltol capsule, Ferric maltol suspension; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia
Interventions: Right Heart Catheterization, Blood draw; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 36
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 31 more

Conditions: Chronic Kidney Disease, Iron-deficiency Anemia
Interventions: IV Iron, Ferrous Sulfate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Iron Overload
Interventions: SP-420; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions: deferasirox; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions: Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Peripheral Arterial Disease (PAD)
Interventions: ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions: Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Iron Overload, Hemosiderosis
Interventions: Non-contrast MRI; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 10 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: 3D-printed ingestible pill; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Iron Deficiency Anemia
Interventions: Sodium ferric gluconate; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Malignant Glioma
Interventions: T2 (Observed)-Weighted Imaging, Biospecimen Collection, Magnetic Resonance Imaging; Procedure
Lead sponsor: John M. Buatti; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Anemia, Myelodysplastic Syndrome
Interventions: Deferasirox, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pregnancy
Interventions: Encapsulated Calcium, Non-capsulated Calcium; Dietary Supplement
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Baltimore, Maryland • Houston, Texas

Conditions: Iron-deficiency, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment, Iron Deficiency Anemia
Interventions: Ferrous sulfate, Ferrous sulfate-enriched Aspergillus oryzae (Ao iron); Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Iron Deficiency, Fibromyalgia
Interventions: Injectafer, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Chronic Kidney Disease, Anemia of Chronic Disease
Interventions: Oral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Iron Deficiency (ID), Pregnancy
Interventions: Lactiplantibacillus plantarum 299v, Placebo Capsule(s); Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Modulation of Cerebral Blood Flow Using Iron Chelators

Ketamine and Nitroprusside for Depression

A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

Safety of SP-420 in the Treatment of Transfusional Iron Overload

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)

Estrogen and Microvascular Function

Non-invasive Quantification of Liver Iron With MRI

Gut Microbiome Pill

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Encapsulated Calcium Absorption in Pregnancy

Effect of Iron Supplements on the Growth of Enteric Pathogens

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease

Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females